DavidCameronMD

PubMed

• Grk1b and Grk7a Both Contribute to the Recovery of the Isolated Cone Photoresponse in Larval Zebrafish.
  Chrispell, J. D.,Dong, E.,Osawa, S.,Liu, J.,Cameron, D. J.,Weiss, E. R.> ;Invest. Ophthalmol. Vis. Sci.. 2018 Oct 30
• Ecosystem management and land conservation can substantially contribute to California's climate mitigation goals.
  Cameron, D. R.,Marvin, D. C.,Remucal, J. M.,Passero, M. C.> ;Proc. Natl. Acad. Sci. U.S.A.. 2017 Nov 15
• Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.
  Schneider BP, Shen F, Gardner L, Radovich M, Li L, Miller KD, Jiang G, Lai D, O'Neill A, Sparano JA, Davidson NE, Cameron D, Gradus-Pizlo I, Mastouri RA, Suter TM, For...> ;Clin. Cancer Res.. 2016-12-19
• Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast...
  Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Sch...> ;Ann. Oncol.. 2016-12-19
• Trastuzumab-associated cardiac events in the Persephone trial.
  Earl HM, Vallier A, Dunn J, Loi S, Ogburn E, McAdam K, Hughes-Davies L, Harnett A, Abraham J, Wardley A, Cameron DA, Miles D, Gounaris I, Plummer C, Hiller L> ;Br. J. Cancer. 2016-12-06
• Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
  Bartlett JMS, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA, Earl HM, Rea DW, Macpherson IR, Canney P, Francis A, Mc...> ;J. Natl. Cancer Inst.. 2016-09-01
• Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
  Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Pen...> ;Ann. Oncol.. 2016-06-01
• Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
  Lee CK, Davies L, Gebski VJ, Lord SJ, Di Leo A, Johnston S, Geyer C, Cameron D, Press MF, Ellis C, Loi S, Marschner I, Simes J, de Souza P> ;J. Clin. Oncol.. 2016-03-20
• Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies.
  Bergh J, Pritchard KI, Cameron D> ;J. Clin. Oncol.. 2016-03-20
• Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
  Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gr...> ;Ann. Oncol.. 2016-03-01
• Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling.
  Gregory WM, Twelves CJ, Bell R, Smye SW, Howard DR, Coleman RE, Cameron DA> ;Breast Cancer Res. Treat.. 2016-01-01
• Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.
  Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart M, Gelber RD> ;Breast Cancer Res. Treat.. 2016-01-01
• Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints...
  Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cuf...> ;Ann. Oncol.. 2015-12-01
• Reelin Prevents Apical Neurite Retraction during Terminal Translocation and Dendrite Initiation.
  O'Dell RS, Cameron DA, Zipfel WR, Olson EC> ;J. Neurosci.. 2015-07-29
• Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
  Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badv...> ;Ann. Oncol.. 2015-07-01
• Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.
  Bartlett JMS, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen M, Caldas C, Twelves ...> ;J. Clin. Oncol.. 2015-05-20
• Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints...
  Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cuf...> ;Ann. Oncol.. 2015-05-01
• Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of th...
  Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tred...> ;Ann. Oncol.. 2015-02-01
• The Effect of Zeaxanthin on the Visual Acuity of Zebrafish.
  Saidi EA, Davey PG, Cameron DJ> ;PLoS ONE. 2015-01-01
• A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
  Cowan J, Gaudet L, Mulpuru S, Corrales-Medina V, Hawken S, Cameron C, Aaron SD, Cameron DW> ;PLoS ONE. 2015-01-01
• Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer.
  Stephen J, Murray G, Cameron DA, Thomas J, Kunkler IH, Jack W, Kerr GR, Piper T, Brookes CL, Rea DW, van de Velde CJH, Hasenburg A, Markopoulos C, Dirix L, Seynaeve C,...> ;Br. J. Cancer. 2014-12-09
• Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.
  Moossdorff M, van Roozendaal LM, Strobbe LJA, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kühn T, Lippman ME, L...> ;J. Natl. Cancer Inst.. 2014-12-01
• The AURORA initiative for metastatic breast cancer.
  Zardavas, D.,Maetens, M.,Irrthum, A.,Goulioti, T.,Engelen, K.,Fumagalli, D.,Salgado, R.,Aftimos, P.,Saini, K. S.,Sotiriou, C.,Campbell, P.,Dinh, P.,von Minckwitz, G.,G...> ;Br. J. Cancer. 2014 Sep 17
• Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
  de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Ley...> ;J. Clin. Oncol.. 2014-07-10
• 19 citations
  The VACS index accurately predicts mortality and treatment response among multi-drug resistant HIV infected patients participating in the options in management with an...
  Sheldon T. Brown, Janet P. Tate, Tassos C. Kyriakides, Katherine A. Kirkwood, Mark Holodniy, Joseph L. Goulet, Brian Angus, D. William Cameron, Amy C. Justice> ;Plos One. 2014 Mar 25
• Join now to see all